Alkem Laboratories Ltd
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
- Market Cap ₹ 55,195 Cr.
- Current Price ₹ 4,616
- High / Low ₹ 5,520 / 3,186
- Stock P/E 32.1
- Book Value ₹ 848
- Dividend Yield 0.76 %
- ROCE 13.2 %
- ROE 12.6 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.4%
Cons
- The company has delivered a poor sales growth of 11.4% over past five years.
- Tax rate seems low
- Promoter holding has decreased over last 3 years: -5.69%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,924 | 2,291 | 2,660 | 3,072 | 3,911 | 4,548 | 5,281 | 5,714 | 6,677 | 7,220 | 8,830 | 9,055 | 9,620 | |
1,529 | 1,860 | 2,261 | 2,722 | 3,180 | 3,668 | 4,308 | 4,667 | 5,209 | 5,268 | 7,018 | 7,665 | 7,731 | |
Operating Profit | 396 | 432 | 399 | 350 | 731 | 880 | 973 | 1,048 | 1,468 | 1,951 | 1,812 | 1,389 | 1,890 |
OPM % | 21% | 19% | 15% | 11% | 19% | 19% | 18% | 18% | 22% | 27% | 21% | 15% | 20% |
146 | 166 | 164 | 177 | 240 | 115 | 101 | 66 | 96 | 175 | 199 | 254 | 247 | |
Interest | 53 | 79 | 84 | 73 | 59 | 24 | 32 | 28 | 39 | 43 | 38 | 86 | 83 |
Depreciation | 28 | 36 | 43 | 60 | 74 | 76 | 108 | 141 | 187 | 199 | 219 | 230 | 232 |
Profit before tax | 460 | 482 | 436 | 395 | 839 | 894 | 934 | 944 | 1,338 | 1,884 | 1,753 | 1,327 | 1,822 |
Tax % | 6% | 3% | -1% | 7% | 17% | 1% | 23% | 15% | 6% | 11% | 12% | 15% | |
432 | 467 | 440 | 368 | 700 | 883 | 716 | 800 | 1,264 | 1,685 | 1,541 | 1,134 | 1,677 | |
EPS in Rs | 361.15 | 390.40 | 368.17 | 30.75 | 58.56 | 73.86 | 59.87 | 66.90 | 105.75 | 140.93 | 128.90 | 94.88 | 140.25 |
Dividend Payout % | 6% | 5% | 5% | 13% | 22% | 20% | 22% | 24% | 24% | 21% | 26% | 53% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 11% |
3 Years: | 11% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | -3% |
TTM: | 80% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 19% |
1 Year: | 35% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 18% |
3 Years: | 18% |
Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Reserves | 1,852 | 2,291 | 2,703 | 3,077 | 3,576 | 4,369 | 4,861 | 5,441 | 6,257 | 7,602 | 8,720 | 9,326 | 10,121 |
824 | 1,229 | 947 | 1,103 | 380 | 368 | 548 | 503 | 1,209 | 1,384 | 2,294 | 1,182 | 823 | |
478 | 479 | 540 | 657 | 843 | 1,137 | 1,381 | 1,324 | 1,616 | 1,763 | 2,132 | 2,200 | 2,459 | |
Total Liabilities | 3,166 | 4,011 | 4,202 | 4,861 | 4,822 | 5,898 | 6,814 | 7,292 | 9,106 | 10,773 | 13,169 | 12,731 | 13,427 |
665 | 832 | 909 | 870 | 875 | 1,126 | 1,471 | 1,606 | 1,837 | 1,758 | 1,882 | 1,825 | 1,924 | |
CWIP | -0 | -0 | -0 | 96 | 147 | 218 | 299 | 382 | 314 | 323 | 232 | 229 | 77 |
Investments | 372 | 579 | 940 | 1,071 | 1,158 | 1,518 | 1,544 | 1,696 | 1,956 | 2,152 | 2,529 | 3,006 | 3,002 |
2,129 | 2,600 | 2,352 | 2,824 | 2,644 | 3,037 | 3,500 | 3,609 | 4,999 | 6,539 | 8,526 | 7,672 | 8,424 | |
Total Assets | 3,166 | 4,011 | 4,202 | 4,861 | 4,822 | 5,898 | 6,814 | 7,292 | 9,106 | 10,773 | 13,169 | 12,731 | 13,427 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
152 | 97 | 264 | 242 | 630 | 499 | 318 | 745 | 682 | 1,324 | 1,299 | 1,437 | |
-279 | -349 | 119 | -260 | 311 | -362 | -273 | -313 | -995 | -1,121 | -1,669 | 197 | |
19 | 274 | -395 | 26 | -958 | -125 | -60 | -276 | 173 | -209 | 437 | -1,711 | |
Net Cash Flow | -108 | 21 | -12 | 8 | -17 | 13 | -15 | 156 | -141 | -5 | 67 | -77 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 48 | 46 | 40 | 45 | 45 | 51 | 60 | 62 | 85 | 79 | 73 | 71 |
Inventory Days | 146 | 183 | 161 | 143 | 139 | 175 | 180 | 159 | 156 | 207 | 202 | 164 |
Days Payable | 122 | 103 | 88 | 90 | 110 | 139 | 144 | 121 | 116 | 131 | 114 | 103 |
Cash Conversion Cycle | 71 | 127 | 113 | 97 | 74 | 86 | 97 | 100 | 125 | 155 | 162 | 133 |
Working Capital Days | 55 | 90 | 68 | 63 | 45 | 59 | 81 | 82 | 105 | 113 | 106 | 96 |
ROCE % | 21% | 18% | 15% | 11% | 22% | 21% | 19% | 17% | 20% | 23% | 18% | 13% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI LODR - Regulatory Order
16 Apr - The Company has received an order passed by statutory authority under Goods and Services Tax Act, 2017. The relevant disclosure is enclosed herewith.
- Reply To BSE Email - Additional Details Required Under SEBI Circular Dated July 13, 2023, For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 12 Apr
- Compliances- Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2024. 11 Apr
-
Compliance Certificate For The Period Ended March, 2024.
10 Apr - With reference to the subject matter, please find enclosed herewith the Compliance Certificate under Regulation 7 (3) of SEBI (LODR) Regulations, 2015, duly signed by …
- Reply To BSE Limited - Outcome Of The 49Th Annual General Meeting Of The Company. 8 Apr
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptPPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017Transcript PPT
-
Jan 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
May 2016TranscriptPPT
-
Feb 2016Transcript PPT
Leading Pharmaceutical company[1] Alkem is the fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022.
It has established its leadership position in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments.